Verona Pharma Plc (VRP) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 26 PAGES: 35

More Info
									              Verona Pharma Plc (VRP) - Financial and Strategic SWOT Analysis
                                          Review
        Reference Code: GDPH96168FSA                                                                                             Publication Date: AUG 2012

          Suite 21 - Alpha House, 100 Borough
                                                             Phone              +44 20 78633300                     Revenue         NA
          High Street
          London, ENG                                        Fax                +44 20 78633314                     Net Profit      -1.72 (million GBP)
          SE1 1LB                                            Website            www.veronapharma.com                Employees       NA
                                                                                VRP      [SEATS        (AIM                         Pharmaceuticals            &
          United Kingdom                                     Exchange                                               Industry
                                                                                Market)]                                            Healthcare

       Company Overview
       Verona Pharma Plc (Verona Pharma), formerly known as Isis Resources plc, is a biotechnology company with the focus on the
       research, discovery and development of therapeutic drugs for the treatment of chronic respiratory and inflammatory diseases.
       The company focuses on the development of drugs for the treatment of allergic rhinitis and other chronic respiratory diseases,
       including asthma and chronic obstructive pulmonary disease (COPD), as well as chronic inflammatory diseases.
       Key Executives                                                                SWOT Analysis
                       Name                                Title                      Verona Pharma Plc, SWOT Analysis
         Claire Poll                         Director                                 Strengths                                Weaknesses
         Jan-Anders Karlsson, Ph.D. Chief Executive Officer
                                                                                      Strong Liquidity Position                Negative Margins
         Clive Page, Ph.D.                   Chairman
                                                                                      Virtual R&D Model
         Trevor Jones                        Director
         Stuart Bottomley                    Director
        Source: Annual Report, Company Website, Primary and Secondary
                                                                                      Opportunities                            Threats
        Research, GlobalData
                                                                                      Strategic Agreements and                 Uncertain R&D Outcomes
       Share Data                                                                     Collaborations
                                                                                                                               Growing Parallel Trade
         Verona Pharma Plc
                                                                                      Emerging Markets
        Share Price (GBP) as on 23-Aug-                                  0.05
        2012
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        EPS (GBP)                                                       -0.01        GlobalData
        Market Cap (million GBP)                                            9
        Enterprise Value (million GBP)                                      7
        Shares Outstanding (million)                                     307
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      May 01, 2012         Verona Pharma Appoints Sven Karlsson As
                                                                                                           New CEO
                                                                                      Apr 05, 2012         Verona Pharma Reports 2011 Results
                                                                                      Sep 07, 2011         Verona Pharma Reports H1 2011 Results
                                                                                      Mar 23, 2011         Verona Pharma Reports Net Loss Of £1.9m
                                                                                                           For 2010
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData



       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Verona Pharma Plc (VRP) - Financial and Strategic SWOT Analysis                                                                   Reference Code: GDPH96168FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                         Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Verona Pharma Plc - Key Facts ......................................................................................................................................................... 5
       Verona Pharma Plc - Key Employees ................................................................................................................................................ 6
       Verona Pharma Plc - Key Employee Biographies .............................................................................................................................. 7
       Verona Pharma Plc - Major Products and Services ........................................................................................................................... 8
       Verona Pharma Plc - Pharmaceutical Pipeline Products Data ........................................................................................................... 9
          Verona Pharma Plc, Pipeline Products by Therapy Area................................................................................................................ 9
          Verona Pharma Plc, Pipeline Products by Development Phase ................................................................................................... 10
       Verona Pharma Plc - History ............................................................................................................................................................ 12
       Verona Pharma Plc - Company Statement....................................................................................................................................... 14
       Verona Pharma Plc - Locations And Subsidiaries ............................................................................................................................ 15
          Head Office ................................................................................................................................................................................... 15
          Other Locations & Subsidiaries ..................................................................................................................................................... 15
       Section 2 – Company Analysis ......................................................................................................................................................... 16
       Verona Pharma Plc - Business Description ...................................................................................................................................... 16
       Verona Pharma Plc - Corporate Strategy ......................................................................................................................................... 17
       Verona Pharma Plc - SWOT Analysis .............................................................................................................................................. 18
          SWOT Analysis - Overview........................................................................................................................................................... 18
          Verona Pharma Plc - Strengths .................................................................................................................................................... 18
             Strength - Strong Liquidity Position ........................................................................................................................................... 18
             Strength - Virtual R&D Model .................................................................................................................................................... 18
             Strength - Focused Product Development Efforts ..................................................................................................................... 18
          Verona Pharma Plc - Weaknesses ............................................................................................................................................... 18
             Weakness - Negative Margins .................................................................................................................................................. 18
          Verona Pharma Plc - Opportunities .............................................................................................................................................. 19
             Opportunity - Strategic Agreements and Collaborations ........................................................................................................... 19
             Opportunity - Emerging Markets ............................................................................................................................................... 19
             Opportunity - Market Potential: Respiratory Disorders .............................................................................................................. 19
          Verona Pharma Plc - Threats ....................................................................................................................................................... 19
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 19
             Threat - Growing Parallel Trade ................................................................................................................................................ 20
             Threat - Competitive Pressures ................................................................................................................................................. 20
       Verona Pharma Plc - Key Competitors ............................................................................................................................................. 21
       Section 3 – Company Financial Ratios ............................................................................................................................................. 22
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 22
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 22
       Performance Chart ........................................................................................................................................................................... 23
       Financial Performance...................................................................................................................................................................... 23
       Financial Ratios - Interim Ratios....................................................................................................................................................... 24
       Financial Ratios - Ratio Charts ..........................................................................
								
To top